BRAF inhibitor therapy–associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression-Reference-Cited by-同舟云学术

BRAF inhibitor therapy–associated melanocytic lesions lack the BRAF V600E mutation and show increased levels of cyclin D1 expression

Published:2016-04 Issue: Volume:50 Page:79-89
ISSN:0046-8177
Container-title:Human Pathology
language:en
Short-container-title:Human Pathology

Author:

Mudaliar Kumaran,Tetzlaff Michael T.,Duvic Madeleine,Ciurea Ana,Hymes Sharon,Milton Denái R.,Tsai Kenneth Y.,Prieto Victor G.,Torres-Cabala Carlos A.,Curry Jonathan L.

Publisher

Elsevier BV

Subject

Pathology and Forensic Medicine

Reference36 articles.

1. Results of a phase III, randomized, placebo-controlled study of sorafenib in combination with carboplatin and paclitaxel as second-line treatment in patients with unresectable stage III or stage IV melanoma;Hauschild;J Clin Oncol,2009

2. Extended schedule, escalated dose temozolomide versus dacarbazine in stage IV melanoma: final results of a randomised phase III study (EORTC 18032);Patel;Eur J Cancer,2011

3. A pooled analysis of Eastern Cooperative Oncology Group and intergroup trials of adjuvant high-dose interferon for melanoma;Kirkwood;Clin Cancer Res,2004

4. Improved survival with vemurafenib in melanoma with BRAF V600E mutation;Chapman;N Engl J Med,2011

5. Cutaneous toxic effects associated with vemurafenib and inhibition of the BRAF pathway;Huang;Arch Dermatol,2012

Cited by 18 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Eruptive Melanocytic Nevi in the Setting of Encorafenib, Cetuximab, and Binimetinib Combination Therapy: A Case Report;Case Reports in Dermatology;2024-05-28

2. Traumatized and Recurrent Melanocytic Nevi;Melanocytic Tumors of the Skin;2024-02-01

3. Diverse landscape of dermatologic toxicities from small‐molecule inhibitor cancer therapy;Journal of Cutaneous Pathology;2021-10-21

4. Cutaneous reactions in children treated with MEK inhibitors, BRAF inhibitors, or combination therapy: A multicenter study;Journal of the American Academy of Dermatology;2021-06

5. New primary melanoma in a patient under triple therapy with vemurafenib, cobimetinib, and atezolizumab for metastatic melanoma;Melanoma Research;2020-04